Featured articles

Other articles

Newormics is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of <span style="color: #404040">. . .</span><br><br><p style="color: #1161e1">READ MORE →</p>

Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and <span style="color: #404040">. . .</span><br><br><p style="color: #1161e1">READ MORE →</p>

Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project <span style="color: #404040">. . .</span><br><br><p style="color: #1161e1">READ MORE →</p>

Newormics is exhibiting at the 22nd International C. elegans Conference at UCLA, Los Angeles from 20th June - 24th June. <span style="color: #404040">. . .</span><br><br><p style="color: #1161e1">READ MORE →</p>

Newormics was selected for the NIH I-Corps April-June 2019 cohort. Over the course of the I-Corps program, the team had <span style="color: #404040">. . .</span><br><br><p style="color: #1161e1">READ MORE →</p>

Newormics was awarded an SBIR Phase I grant from the National Institute of Mental Health (NIMH) for the project "A <span style="color: #404040">. . .</span><br><br><p style="color: #1161e1">READ MORE →</p>

Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models <span style="color: #404040">. . .</span><br><br><p style="color: #1161e1">READ MORE →</p>